Merida Biosciences has emerged from Third Rock Ventures with $121 million in first-round financing for a pipeline of drugs ...

Explore how nanosensors are transforming cancer diagnostics by enabling earlier, more accurate, and less invasive detection ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.

Q1 2023 Earnings Call Transcript April 15, 2025 Spruce Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0 ...

3D reconstruction of labeled PTK7 and NCL distribution in live ... It could pave the way for next-generation antibody-drug conjugates (ADCs) targeting specific cancer cells, bioimaging ...

Array Bridge is testing promising drug candidates that can effectively bind and even degrade target proteins, but not via ...

The treatment strategy for congenital adrenal hyperplasia is burdensome and had not changed in more than 70 years until the ...

The regulatory submission was based on the results of an open-label Phase 3 test that compared ... The drug is an antibody drug conjugate designed to target the cancer protein TROP2.

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules), ...

“Vaccines will aid in the prevention of disease, but it doesn’t mean the sheep are not going to get sick,” she said. “The ...

Notably, the researchers succeeded in bio-orthogonal labeling of two key cancer biomarker ... It could pave the way for next-generation antibody-drug conjugates (ADCs) targeting specific cancer ...